Island Pharmaceuticals Income Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Operating Revenue	0.05	0.11	1.25	-	-	-
Other Revenue	0.01	0.01	0.01	-	-	-
Revenue	0.06	0.12	1.26	-	-	-
Revenue Growth (YoY)	-84.26%	-90.57%	-	-	-	-
Cost of Revenue	2.05	1.4	2.27	1.14	-	-
Gross Profit	-1.99	-1.29	-1.01	-1.14	-	-
Selling, General & Admin	2.68	2.33	1.85	1.77	1.78	2.14
Research & Development	-	-	-	-	1.03	0
Operating Expenses	5.38	2.67	1.85	1.77	2.81	2.14
Operating Income	-7.36	-3.96	-2.86	-2.91	-2.81	-2.14
Interest Expense	-	-0.03	-0.05	-0.01	-	-
Interest & Investment Income	0.17	0.06	0	0.01	-	-
Currency Exchange Gain (Loss)	-0	0	0.04	0.08	0.2	0.01
Pretax Income	-7.2	-3.92	-2.86	-2.83	-2.61	-2.13
Net Income	-7.2	-3.92	-2.86	-2.83	-2.61	-2.13
Net Income to Common	-7.2	-3.92	-2.86	-2.83	-2.61	-2.13
Shares Outstanding (Basic)	228	173	90	81	81	19
Shares Outstanding (Diluted)	228	173	90	81	81	19
Shares Change (YoY)	88.25%	91.98%	11.11%	0.42%	334.32%	-
EPS (Basic)	-0.03	-0.02	-0.03	-0.03	-0.03	-0.11
EPS (Diluted)	-0.03	-0.02	-0.03	-0.03	-0.03	-0.11
Gross Margin	-	-	-80.14%	-	-	-
Operating Margin	-11715.94%	-3326.06%	-227.00%	-	-	-
Profit Margin	-11452.57%	-3296.73%	-227.04%	-	-	-
EBIT	-7.36	-3.96	-2.86	-2.91	-2.81	-2.14
EBIT Margin	-	-	-227.00%	-	-	-
Revenue as Reported	0.23	0.18	1.27	0.01	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.